SASteen Lomborg Andersen

Steen Lomborg Andersen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Steen Lomborg Andersen has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Predictors of 30-day readmission in patients with bloodstream infection: a population-based cohort study

    by Kim Oren Gradel, Pavithra Laxsen Anru, Stig Lønberg Nielsen, Sofie Skovmand, Ram Benny Dessau, Jens Kjølseth Møller, Steen Lomborg Andersen, Thøger Gorm Jensen, John Eugenio Coia, Mette Søgaard

    Summary Purpose To identify predictors of hospital readmissions within 30 days after discharge following a bloodstream infection (BSI). Methods Population-based study of 30,843 patients surviving after their first BSI episode, 2007–2016. Using multivariate competing risk regression analyses, we estimated subhazard ratios (sHRs) and 95% confidence intervals (CIs) for all-cause, infection-related, and unplanned readmissions. Predictors included sex, age, comorbidities, causative microorganisms, length of stay (LOS), and prior hospital admissions. Results Within 30 days of discharge, 9655 patients (31.3%) were readmitted of which 3333 (34.5%) were infection-related and 7725 (80.0%) unplanned. Higher risks of all-cause readmissions were observed for males (sHR [95% CI]: 1.07 [1.03–1.12]), those aged 0–15 years (1.41 [1.26–1.58]), and patients with several comorbidities, especially malignancies and liver diseases (sHR 1.26–2.09). BSIs caused by most microorganisms other than Escherichia coli also predicted an increased readmission risk (sHR 1.11–1.39). LOS in the first, third, and fourth quartiles also predicted a higher readmission risk (sHR 1.26, 1.14, and 1.25, respectively). Patients with prior hospitalization also had a higher readmission risk, within 31–365 (sHR 1.22 [1.16–1.28]) and 1–30 days (1.70 [1.61–1.79]). Results were similar for unplanned readmissions. For infection-related readmissions, only LOS in the first quartile (1–5 days) was associated with a higher readmission risk (1.67 [1.52–1.85]). Over the study period, the median LOS decreased, whereas readmission rates increased. Conclusion Nearly one-third of patients discharged alive after a BSI were readmitted within 30 days. Further studies are needed to determine whether some of these readmissions may be avoidable.


  • Open Access

    Evaluation of point-of-care multiplex polymerase chain reaction in guiding antibiotic treatment of patients acutely admitted with suspected community-acquired pneumonia in Denmark: A multicentre randomised controlled trial

    by Mariana Bichuette Cartuliares, Flemming Schønning Rosenvinge, Christian Backer Mogensen, Thor Aage Skovsted, Steen Lomborg Andersen, Claus Østergaard, Andreas Kristian Pedersen, Helene Skjøt-Arkil

    Background: Rapid and accurate detection of pathogens is needed in community-acquired pneumonia (CAP) to enable appropriate antibiotics and to slow the development of antibiotic resistance. We aimed to compare the effect of point-of-care (POC) polymerase chain reaction (PCR) detection of respiratory pathogens added to standard care with standard care only (SCO) on antibiotic prescriptions after acute hospital admission. Methods and findings: We performed a superiority, parallel-group, open-label, multicentre, randomised controlled trial (RCT) in 3 Danish medical emergency departments (EDs) from March 2021 to February 2022. Adults acutely admitted with suspected CAP during the daytime on weekdays were included and randomly assigned (1:1) to POC-PCR (The Biofire FilmArray Pneumonia Panel plus added to standard care) or SCO (routine culture and, if requested by the attending physician, target-specific PCR) analysis of respiratory samples. We randomly assigned 294 patients with successfully collected samples (tracheal secretion 78.4% or expectorated sputum 21.6%) to POC-PCR (n = 148, 50.4%) or SCO (146, 49.6%). Patients and investigators owning the data were blinded to the allocation and test results. Outcome adjudicators and clinical staff at the ED were not blinded to allocation and test results but were together with the statistician, blinded to data management and analysis. Laboratory staff performing standard care analyses was blinded to allocation. The study coordinator was not blinded. Intention-to-treat and per protocol analysis were performed using logistic regression with Huber–White clustered standard errors for the prescription of antibiotic treatment. Loss to follow-up comprises 3 patients in the POC-PCR (2%) and none in the SCO group. Intention-to-treat analysis showed no difference in the primary outcome of prescriptions of no or narrow-spectrum antibiotics at 4 h after admission for the POC-PCR (n = 91, 62.8%) odds ratio (OR) 1.13; (95% confidence interval (CI) [0.96, 1.34] p = 0.134) and SCO (n = 87, 59.6%). Secondary outcomes showed that prescriptions were significantly more targeted at 4-h OR 5.68; (95% CI [2.49, 12.94] p < 0.001) and 48-h OR 4.20; (95% CI [1.87, 9.40] p < 0.001) and more adequate at 48-h OR 2.11; (95% CI [1.23, 3.61] p = 0.006) and on day 5 in the POC-PCR group OR 1.40; (95% CI [1.18, 1.66] p < 0.001). There was no difference between the groups in relation to intensive care unit (ICU) admissions OR 0.54; (95% CI [0.10, 2.91] p = 0.475), readmission within 30 days OR 0.90; (95% CI [0.43, 1.86] p = 0.787), length of stay (LOS) IRR 0.82; (95% CI [0.63, 1.07] p = 0.164), 30 days mortality OR 1.24; (95% CI [0.32, 4.82] p = 0.749), and in-hospital mortality OR 0.98; (95% CI [0.19, 5.06] p = 0.986). Conclusions: In a setting with an already restrictive use of antibiotics, adding POC-PCR to the diagnostic setup did not increase the number of patients treated with narrow-spectrum or without antibiotics. POC-PCR may result in a more targeted and adequate use of antibiotics. A significant study limitation was the concurrent Coronavirus Disease 2019 (COVID-19) pandemic resulting in an unusually low transmission of respiratory virus. Trial registration: ClinicalTrials.gov (NCT04651712).


  • Top Cited Papers
    Open Access

    Increase in invasive group A streptococcal infections and emergence of novel, rapidly expanding sub-lineage of the virulent Streptococcus pyogenes M1 clone, Denmark, 2023

    by Thor Bech Johannesen, Charlotte Munkstrup, Sofie Marie Edslev, Sharmin Baig, Stine Nielsen, Tjede Funk, Dennis Karsten Kristensen, Lars Hervig Jacobsen, Signe Fischer Ravn, Niels Bindslev, et al.

    A highly virulent sub-lineage of the Streptococcus pyogenes M1 clone has been rapidly expanding throughout Denmark since late 2022 and now accounts for 30% of the new invasive group A streptococcal infections. We aimed to investigate whether a shift in variant composition can account for the high incidence rates observed over winter 2022/23, or if these are better explained by the impact of COVID-19-related restrictions on population immunity and carriage of group A Streptococcus.